Thompson L Alexa, Fenton Jayne, Charlton Carmen L
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
Alberta Precision Laboratories (ProvLab), University of Alberta Hospital, University of Alberta, Edmonton, Alberta, Canada.
J Assoc Med Microbiol Infect Dis Can. 2022 Jun 3;7(2):97-107. doi: 10.3138/jammi-2021-0028. eCollection 2022 Jun.
Hepatitis C virus (HCV) can be cured with antiviral treatments. Diagnosis normally requires two blood samples, one for serology screening and one for molecular confirmation. This multi-step process creates barriers in patient care and decreases testing for hard-to-reach populations. We used the cobas® 6800 to detect HCV RNA after antibody testing to investigate whether a single-sample reflex testing method is effective and efficient for diagnosing HCV-positive patients.
HCV RNA-positive clinical samples ( = 152) were interchangeably loaded on the ARCHITECT i2000SR with negative samples ( = 152) in a checkerboard fashion, tested for HCV antibodies using fixed probes, and directly transferred to the cobas 6800 for molecular testing. Contamination rates, sensitivity, and specificity were determined by comparing Abbott m2000 and cobas 6800 viral loads. After implementing reflex testing, clinical data over a 6-month period were analyzed for diagnostic efficiency.
Contamination was present in 5 of 152 pairs (3.29%) after reflex testing. Sensitivity and specificity were 99.3% (95% CI 95.1% to 99.9%) and 100% (95% CI 97.5% to 100%), respectively, using the cobas 6800 assay after serotesting. Approximately 97% of clinical patients received a conclusive test result with the reflex-testing algorithm. For HCV-positive patients, mean diagnostic turnaround times were significantly lower using reflex testing versus the two-sample method (4 versus 39 days; < 0.0001).
HCV reflex testing demonstrated low levels of contamination without compromising the integrity of the molecular assay. Implementation in clinical laboratories would increase the efficiency of diagnosis and decrease steps in the continuum of care for patients.
丙型肝炎病毒(HCV)可通过抗病毒治疗治愈。通常诊断需要两份血样,一份用于血清学筛查,另一份用于分子确认。这种多步骤过程给患者护理带来障碍,并减少了对难以接触人群的检测。我们在抗体检测后使用cobas® 6800检测HCV RNA,以研究单样本反射检测方法对诊断HCV阳性患者是否有效且高效。
将HCV RNA阳性临床样本(n = 152)与阴性样本(n = 152)以棋盘式方式交替加载到ARCHITECT i2000SR上,使用固定探针检测HCV抗体,然后直接转移到cobas 6800进行分子检测。通过比较雅培m2000和cobas 6800病毒载量来确定污染率、灵敏度和特异性。实施反射检测后,分析6个月期间的临床数据以评估诊断效率。
反射检测后,152对样本中有5对(3.29%)存在污染。血清学检测后使用cobas 6800检测法,灵敏度和特异性分别为99.3%(95%CI 95.1%至99.9%)和100%(95%CI 97.5%至100%)。约97%的临床患者通过反射检测算法获得了确定性检测结果。对于HCV阳性患者,与双样本方法相比,反射检测的平均诊断周转时间显著缩短(4天对39天;P < 0.0001)。
HCV反射检测显示污染水平较低,且不影响分子检测的完整性。在临床实验室实施将提高诊断效率,并减少患者连续护理中的步骤。